AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03915886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets will be administered orally.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 7.5 mg
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 12.5 mg
Description: ZSP1603 capsule administered orally once daily in the fasting state.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 12.5mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 25 mg
Description: ZSP1603 capsule administered orally once daily under fasted condition.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 25mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1603 50 mg
Description: ZSP1603 capsule administered orally once daily under fasted state.
Study NCT03619616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 50mg
Description: Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
Study NCT04191954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fasudil eye drops (concentration 0.5 percent)
Description: receive Fasudil eye drops (concentration 0.5 percent) twice daily
Study NCT04191954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: receive artificial tears drop
Description: receive artificial tears drop with the same frequency
Study NCT01304849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escalated BEACOPP
Description: Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm
Study NCT04540497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Inebilizumab is a monoclonal antibody that depletes B cells.
Study NCT04540497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02425449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
Study NCT02899000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel
Description: Topical acne therapy
Study NCT02899000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral doxycycline hyclate
Description: Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)
Study NCT02957812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made Foot Orthotics (CFO)
Description: Provides longitudinal arch support
Study NCT04575493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crano-cure
Description: Research literatures have revealed that Tribulus terrestris (Gokhro), Vaccinium macrocarpon (karonda), Cuminum cyminum (Zeera sufaid), Rheum emodi (Revand chini) and Piper cubeba (Kabab chini) are important therapeutic plants. Many pharmacological researches have been done on these plants. For instance, antioxidant, antiseptic, anti-microbial, anti-bacterial, anticancer etc. In the above claims and facts, the study is conducted to formulate and evaluate the polyherbal capsule and to find out the most effective combination having anti-bacterial activity.
Study NCT04575493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500 mg
Description: Being a standard drug as antibiotic and will be used in Control group.
Study NCT04065932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165-01
Description: Participants will receive BMS- 986165 -01 in prototype formulation
Study NCT04065932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165 Tablet
Description: Participants will receive BMS-986165 in tablet form.
Study NCT04065932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
Study NCT02716220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Implanttaion fo the DREAMS 2G Scaffold
Study NCT03483519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
Study NCT03483519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
Study NCT06076980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: compare the hemodynamic parameters of paracetamol as bolus versus extended infusion
Study NCT06076980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: as placebo
Study NCT04947072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
Study NCT04947072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The block will be performed at the level of T9 on the site that will be operated and patient will be given Bupivacaine isobaric 0.5% 25 ml with epinephrine 1:200.000
Study NCT04947072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
Study NCT04947072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Patient will be given bupivacaine hyperbaric 0.5% 16-18 mg at the level of L3-L4 or L4-L5
Study NCT01580293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Intravenous infusion of BAY94-9027
Study NCT00812617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water (Hita, Oita, Japan)
Study NCT00812617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water (Aso-gun, Kumamoto, Japan)
Study NCT04451187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.
Study NCT02761213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: Oral sulfate solution (OSS)
Study NCT02761213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-L PEG/Asc
Description: Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
Study NCT02427295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin (Octreotide Acetate)
Description: For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection.
Study NCT01485484 — intervention group
Intervention type: DEVICE
Intervention: Optic imaging use near-infrared trans-illumination methods
Description: Optic imaging use near-infrared trans-illumination methods
Study NCT02404519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Menaquinone-7
Description: 1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
Study NCT02404519 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet without MK-7 taken orally every day during 1 year
Study NCT00254293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
Study NCT01778127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Measurement of physical activity.
Study NCT01778127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Website
Description: Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
Study NCT00300274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Corticosteroids standard dose.
Study NCT00719459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: Venofer 20 mg/mL
Study NCT00719459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sucrose
Description: Iron sucrose 20 mg/mL
Study NCT02419261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
Study NCT02419261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgical repair of the anterior cruciate ligament
Study NCT01778127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
Study NCT01206127 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative positioning: Sitting up
Description: Patients in this group should be sitting up in a chair 2 hours postoperative
Study NCT04934904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: On the first day of inclusion, performed T8 bilateral ultrasound-guided erector spinae plane block and indwelling tube will be left + 0.375% ropivacaine 20ml to both sides. Patients will be given injections every 12 h for 7 days.
Study NCT01731041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180mg
Description: Patients will receive 180 mg of ticagrelor
Study NCT01968122 — intervention group
Intervention type: DEVICE
Intervention: intravascular stent therapy
Description: Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
Study NCT01731041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg
Description: Patients will receive 90 mg of ticagrelor
Study NCT03185156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
Study NCT03185156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
Study NCT03802032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Gel
Description: topical lidocaine gel
Study NCT03802032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KY jelly
Description: topical KY jelly
Study NCT01724125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personal electronic medical record
Study NCT01724125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: personal electronic medical record
Study NCT01643759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
Study NCT00389103 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MVA (smallpox vaccine)
Description: 0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
Study NCT01341379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-carbamylglutamate
Description: N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
Study NCT02527551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Massage
Description: 6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
Study NCT02403830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
Study NCT02403830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a 0.9% sodium chloride iv injection
Study NCT02403830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: After methylnaltrexone, patients will receive 5-mg intravenous morphine
Study NCT02403830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: After methylnaltrexone, patients will receive 5-mg intravenous morphine
Study NCT02403830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After morphine administration, patients will receive a 180-mg ticagrelor loading dose
Study NCT02403830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: After morphine administration, patients will receive a 180-mg ticagrelor loading dose
Study NCT04004078 — intervention group
Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
Study NCT01517347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00642980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Study NCT04364737 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma
Description: SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
Study NCT04364737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
Study NCT03937661 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Autologous PRP intra ovarian infusion
Study NCT00642980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
Study NCT00642980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: 300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
Study NCT04147910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356
Study NCT03315884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
Description: Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used.
Study NCT03315884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
Description: Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
Study NCT02494999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
Study NCT02494999 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose